Graticule Asia Macro Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-41,300	Closed	-$6.28M	–	92
2017 Q3	$6.28M	Sell	41,300 -18,555	-31%	-$2.79M	0.29%	50
2017 Q2	$7.71M	Sell	59,855 -14,432	-19%	-$1.74M	0.37%	51
2017 Q1	$8.12M	Buy	+74,287	New	+$6.54M	0.47%	55
2016 Q2	–	Sell	-112,261	Closed	-$8.92M	–	90
2016 Q1	$8.92M	Buy	112,261 +70,633	+170%	+$6.39M	0.7%	34
2015 Q4	$5.24M	Buy	41,628 +26,628	+178%	+$3.21M	0.86%	30
2015 Q3	$1.56M	Buy	+15,000	New	+$1.93M	0.18%	61

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Graticule Asia Macro Advisors's VRTX Position: Q4 2017 in Review

Graticule Asia Macro Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 41,300 shares — an estimated $6.28M sold.

Graticule Asia Macro Advisors first reported a position in VRTX in Q3 2015 and held it in 6 quarters. The position peaked at $8.92M in Q1 2016. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

Graticule Asia Macro Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Graticule Asia Macro Advisors sold 41,300 Vertex Pharmaceuticals shares in Q4 2017, an estimated $6.28M.
Graticule Asia Macro Advisors first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 6 quarters.
Graticule Asia Macro Advisors's Vertex Pharmaceuticals position peaked at $8.92M in Q1 2016.
644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.